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ABSTRACT 
Background: Hypertension induces structural vascular and cardiac changes with increased 
arterial stiffness and left ventricular (LV) hypertrophy and is major risk factor for cardio-
vascular morbidity and mortality. The renin-angiotensin-aldosterone system (RAAS) and the 
sympathetic nervous system are important for blood pressure regulation and vascular 
function. Angiotensin II, the main effector of the RAAS, induces vasoconstriction, 
inflammation, structural vascular changes, and LV hypertrophy. Thus, treating hypertension 
with drugs blocking the RAAS might have advantages compared to other drug classes. 
The overall objective of this thesis was to increase our knowledge about the evaluation of 
arterial structure and function in human hypertension. Thus, the effects of treatment on 
indices of arterial stiffness and endothelial function were studied, and the effects beyond 
blood pressure reduction by blocking the RAAS were evaluated by comparison to drugs 
acting on the sympathetic nervous system.  
Material and methods: This work is based on two clinical studies. In the “Swedish 
irbesartan left ventricular hypertrophy versus atenolol project” (SILVHIA), 115 patients with 
hypertension and LV hypertrophy were randomized to treatment based on the AT1-receptor 
blocker irbesartan or the beta-adrenoceptor blocker atenolol for 48 weeks. Two matched 
control groups consisting of hypertensive patients with no LV hypertrophy and normotensive 
control subjects were also investigated. We studied arterial stiffness (by pulse pressure, total 
vascular compliance, and ambulatory arterial stiffness index) and circulating markers of 
inflammation and of endothelial activation. In the “Doxazosin-ramipril study” (DoRa), 71 
hypertensive patients were randomized to treatment with the angiotensin-converting enzyme 
inhibitor ramipril or the alpha 1-adrenoceptor blocker doxazosin for 12 weeks. The effects of 
treatment on arterial stiffness (by pulse wave analysis with applanation tonometry and by an 
oscillometric single-arm cuff method) and on endothelial function were evaluated 
simultaneously in different vascular beds (by forearm flow-mediated vasodilatation, pulse 
wave analysis and beta 2-adrenoceptor agonist stimulation, skin microcirculation by laser 
Doppler fluxmetry and iontophoresis, and myocardial microcirculation by the subendocardial 
viability ratio).  
Results and conclusions: Antihypertensive treatment improved indices of arterial stiffness, 
and blocking the RAAS had additional effects on arterial stiffness beyond blood pressure 
reduction. There were no effects on endothelial function from the treatment. The 
oscillometric single cuff method was a simple and useful method to assess arterial function 
and to evaluate drug-induced treatment effects. Endothelial functions in different vascular 
beds were all related to future cardiovascular mortality risk (according to the “Systematic 
coronary risk evaluation”, SCORE), but not to hypertension-induced heart disease. However, 
the studied methods to evaluate endothelial function were poorly interrelated. Thus, drugs 
blocking the RAAS may offer an advantage in the treatment of hypertension beyond the 
effects on blood pressure reduction, as compared to other drug classes.  
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1 INTRODUCTION 
1.1 BLOOD PRESSURE REGULATION AND THE ROLE OF 
NEUROHORMONAL ACTIVATION  
Essential hypertension is characterized by a disturbance in the central sympathetic nervous 
outflow with increased activation to several organs and a subsequent increase in vascular 
tone. Enhanced noradrenaline release from sympathetic vasoconstrictor nerve endings and 
reduced neuronal reuptake induces vasoconstriction by stimulation of postjunctional alpha 1-
adrenoceptors on vascular smooth muscle cells in the resistance arteries. Impaired 
vasodilation and mechanical shear stress in the vessel walls also contribute to vascular 
remodeling, with further elevation of peripheral vascular resistance (1-3). In addition, 
sympatho-adrenal activation increases cardiac contractility, heart rate, and pulse wave 
amplitude, with an increased pressure workload on the vasculature, thus causing myocardial 
remodeling and impaired cardiac function.  
There are different drugs to reduce theses effects of sympathetic overactivation in 
hypertension. Alpha-adrenoceptor antagonists act on the vasculature to reduce 
vasoconstriction. Also, centrally acting alpha-adrenoceptor agonists acting on inhibitory 
pathways in the control of blood pressure are used to achieve blood pressure reduction. The 
exact mechanism of action through which beta-adrenoceptor antagonists reduce blood 
pressure remains to be established. However, the mechanism is likely to include effects on 
the central nervous system to reduce central sympathetic nervous outflow, and these 
antagonists interact with the renin-angiotensin-aldosterone system (RAAS) by inhibiting beta 
1-adrenoceptor-mediated renin release from the kidneys. In addition, they inhibit beta-
adrenoceptor-mediated chronotropic, inotropic, and lusitropic effects on the myocardium. 
Renal prorenin and renin are synthesized and stored in the juxtaglomerular cells, which are 
located in the vascular walls of the afferent arterioles. Increased renin release is mediated by 
the renal baroreceptor reflex in the afferent arterioles due to a reduction in perfusion pressure. 
Renin release is also stimulated by the juxtaglomerular apparatus due to decreases in tubular 
salt delivery. The juxtaglomerular cells are directly innervated by efferent renal sympathetic 
nerves and postjunctional beta 1-adrenoceptors. In addition, renin release is regulated by 
intracellular calcium levels in the juxtaglomerular cells (4). 
Renin induces formation of angiotensin (ANG) I from circulating angiotensinogen, and ANG 
I is further converted by angiotensin converting enzyme (ACE) to ANG II. ANG II can act on 
ANG II type 1 (AT1)-receptors to mediate vasoconstriction in vascular smooth muscle cells 
and to release vasopressin and aldosterone, leading to retention of water and sodium with 
further increase in blood pressure (BP). In addition, ANG II has trophic, pro-inflammatory, 
and pro-thrombotic effects and can thus induce oxidative stress, hypertrophy, fibrosis, and 
vascular remodeling through AT1-receptor stimulation. ANG II also acts on ANG II type 2 
(AT2)-receptors, which have reciprocal effects compared to AT1-receptor stimulation and 
induce a vascular repair response (Figure 1). Thus, AT2-receptor activation causes 
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vasodilatation by elevation of nitric oxide (NO) synthesis, inhibits cellular growth, and 
promotes cellular differentiation. Recent evidence shows that the RAAS is far more complex 
than this brief description, with different physiologically active peptide fragments of ANG II 
and converting enzymes having both systemic and local effects in different tissues, as 
reviewed elsewhere (4,5). 
 
Figure 1. The renin-angiotensin-aldosterone system and the receptor-mediated effects of angiotensin 
II. ACE, angiotensin converting enzyme, AT1 (angiotensin II type I)-receptor: AT2 (angiotensin II type 
2)-receptor. 
 
Both ACE-inhibitors and AT1-receptor blockers induce vasodilatation. While ACE inhibitors 
prevent formation of ANG II, they also increase levels of bradykinin by inhibiting the 
breakdown of bradykinin by ACE. Bradykinin increases NO synthesis and induces 
vasodilatation (Figure 1). However, AT1-receptor blockers inhibit the direct effects of ANG 
II on AT1-receptors, and this leads to impaired negative feedback and thus increased ANG II 
formation, which will cause increased stimulation of AT2-receptors and might contribute to 
vasodilatation. A consequence of long-term RAAS inhibition is a renin escape mechanism 
with increased synthesis of renin. Direct renin inhibitors can inhibit this compensatory 
mechanism by blocking the renin/prorenin-receptor. Hence, renin production, which is the 
rate-limiting step of ANG II formation, is blocked (6). There is evidence that direct renin 
inhibitors improve vascular structure and function by improving endothelial function and 
reducing the development of atherosclerosis, especially in combination with an AT1-receptor 
blocker (7). Thus, blocking the RAAS at several levels should theoretically be beneficial by 
blocking the compensatory renin increase. However, clinical studies have shown a 
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disadvantage of combination therapy in patients with diabetes with an increased risk of 
hyperkalaemia and cardiovascular (CV) events (8) In addition, there are other therapeutic 
agents under development to modulate the RAAS. In animal models, compound 21, an AT2-
receptor agonist, seems to reduce atherosclerosis (4). 
 
1.2 THE ENDOTHELIUM AND THE ROLE OF ANGIOTENSIN II  
The endothelium is a single cell layer that acts as a semipermeable membrane adherent to the 
vascular lumen. The endothelium is involved in the control of vascular tone, and mechanical 
shear stress and substances stimulating receptors on the endothelial surface can cause 
vasoconstriction or vasodilation. Endothelium-dependent vasodilatation (EDV) is induced by 
NO, which is derived from the transformation of L-arginine to citrulline by the activity of the 
constitutive endothelial enzyme NO synthase. NO causes vasodilatation through relaxation of 
smooth muscle cells by stimulation of cyclic guanosine monophosphate. An increase in NO 
synthesis is caused by mechanical forces on the vessel wall through increased shear stress and 
by endothelial receptor-mediated stimulation by agonists such as acetylcholine (Ach), 
bradykinin, substance P, and serotonin. Also, endothelium-derived relaxing factors like 
prostacyclins and endothelium-derived hyperpolarizing factors can induce vasodilatation if 
less NO is available (9). Vasoconstriction is mediated by ANG II, endothelin 1, thromboxane 
A2, and prostaglandin H2. Increased levels of reactive oxygen species, mainly superoxide 
anion, degenerates NO. ANG II increases oxidative stress, and cytokine release promotes up-
regulation of adhesion molecules and stimulates uptake of oxidized low-density lipoproteins, 
thereby causing vascular remodeling and atherosclerosis (10,11).  
 
1.3 METHODS TO EVALUATE ENDOTHELIAL FUNCTION  
Endothelial function in humans can be studied in different vascular beds, such as the coronary 
circulation, skeletal muscle, and skin microcirculation. The gold standard method to evaluate 
endothelial function in the coronary circulation is to measure changes in coronary blood 
induced by intra-arterial infusion of Ach, which is a measure of EDV (12). The invasive 
forearm blood-flow technique with venous occlusion plethysmography is another reference 
method, where changes in forearm blood flow, which represent modification of the local 
vascular resistance, are measured before and after intra-arterial infusion with Ach and sodium 
nitroprusside (SNP) to represent EDV and endothelium-independent vasodilatation (EIDV), 
respectively (2). Endothelial function in small resistance arteries can be evaluated ex vivo by 
muscular or subcutaneous fat biopsies to evaluate the effects of Ach or SNP in noradrenaline 
precontracted vessels (13). 
Well-established non-invasive methods include post-ischemic flow-mediated vasodilatation 
(FMD) in the brachial artery (14,15) and beta 2-adrenoceptor agonist-induced changes in the 
reflecting pulse wave form as assessed by pulse wave analysis (PWA) with applanation 
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tonometry for skeletal muscle (16,17). Peripheral artery tonometry, where plethysmographic 
pressure changes in the fingertip after arterial occlusion of the forearm (reactive hyperemia 
index) are measured, has been proposed as an alternative method to evaluate endothelial 
function in the peripheral circulation. Skin microvascular reactivity can be measured by laser 
Doppler fluxmetry following post-ischemic or heat-induced hyperaemia or by local 
iontophoretic application of Ach and SNP (18,19). In the myocardium, the subendocardial 
viability ratio (SEVR) can be calculated from PWA with applanation tonometry and the 
aortic pulse waveform, where the ratio of the diastolic to the systolic time pressure index 
gives information about the coronary subendocardial perfusion and microcirculatory function 
(20,21).  
 
1.4 METHODS TO EVALUATE VASCULAR FUNCTION AND INDICES OF 
ARTERIAL STIFFNESS 
A high pulse pressure (i.e. the differences between systolic and diastolic BP) is a simple but 
crude reflection of arterial stiffness. A better measure of vascular elasticity is compliance. 
Arterial compliance is defined as a change in the area, diameter, or volume of an artery or 
arterial bed for a given change in pressure. Thus, one way to define (total) arterial compliance 
is to calculate stroke volume divided by pulse pressure (SV/PP). Hemodynamic changes with 
elevated BP, increased heart rate, and structural vascular changes with loss of elasticity in the 
aorta and larger conduit arteries increase pulse pressure and thus reduce arterial compliance. 
An increased pulsatile load derived from the aorta and conduit arteries also influences smaller 
resistance arteries causing arterial stiffness. Thus, the interaction between the 
macrocirculation and microcirculation in hypertension is important (22).  
In clinical research and in the specialized clinical settings, the use of applanation tonometry 
for PWA is common. PWA of the radial and aortic waveform by applanation tonometry 
allows the central BP, the augmentation index (AIx), and the pulse wave velocity (PWV) to 
be calculated, as presented in Figure 2 (23,24). Interestingly, the Sphygmograph, a 
mechanical device used to measure BP, was developed already in 1854 by German 
physiologist K von Vierordt.  In 1863, French physiologist EJ Marey, improved the device by 
making it portable (25). He demonstrated how this device could graphically show variations 
of the radial pulse waveform using tonometry (see illustration on front page). Today, the 
evaluation of arterial stiffness and central hemodynamic measures can be achieved by 
different techniques. Invasive direct measurements during arterial catheterization, e.g. during 
coronary angiography, is preferable but is more complicated, compared to non-invasive 
methods. PWV and hence arterial stiffness can, in addition to the use of PWA and 
applanation tonometry, also be evaluated by the piezoelectric principle, which is based on the 
time difference of the carotid and femoral pulse wave propagation, or by echo tracking, 
where the pressure curve and flow curve in the common carotid artery are analyzed. 
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The estimation of central BP and indices of arterial stiffness can also be achieved by cuff-
based methods. One single brachial cuff oscillometric method, the Arteriograph, is a device 
where brachial BP readings are registered by an automated arm cuff (26). This technique is 
quick, easy to use, and operator independent, and might thus have important advantages to 
PWA by applanation tonometry. The Arteriograph device has been well validated against 
invasive measurements (27) but has not yet been used for studying the effects of 
antihypertensive treatment on vascular structure and function. Also, comparisons of the two 
methodologies concerning antihypertensive effects on vascular structure and function are 
lacking. This added knowledge about the ability to detect effects of treatment is therefore 
important. 
 
Figure 2. Augmentation Index (AIx) and carotid-femoral pulse wave velocity (PWV). Adapted from 
(24). 
 
1.5 HYPERTENSION-INDUCED CARDIAC AND VASCULAR REMODELING IS 
ASSOCIATED WITH INCREASED CV RISK 
Hypertension-induced cardiac remodeling and the development of left ventricular (LV) 
hypertrophy can reflect LV dysfunction and is associated with an increased risk of 
cardiovascular (CV) morbidity and mortality and all cause death (28,29). Also, vascular 
remodeling, including increased peripheral resistance, increased arterial stiffness with 
elevated pulse wave velocity, and augmented central pulse pressure is all associated with 
increased CV risk (Table 1). In addition, different CV risk factors like hyperglycemia and 
diabetes type 2 accelerate this development and induce early structural vascular changes (30).  
In the microcirculation, hypertension induced remodelling of small resistance arteries has 
prognostic importance, where a greater media-to-lumen ratio is associated with increased risk 
(31). Furthermore, there is an association of structural vascular changes in smaller resistance 
arteries and coronary flow reserve (32). Impaired endothelial function in the forearm 
measured invasively or non-invasively, and in the coronary circulation, measured invasively 
or with ultrasound and Doppler flow as the coronary flow reserve, is related to cardiovascular 
risk according to the Framingham risk score, and is of prognostic importance (12,33,34). 
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There is also a relation between impaired endothelial function in the conduit arteries and 
increased arterial stiffness, augmentation index and central pulse pressure (35,36).  
 
Table 1.  Measurements to evaluate vascular structure and function and indices of arterial stiffness 
and their relation to cardiovascular risk. 
 
 
Method Measurement  Prognosis 
Brachial pulse 
pressure   
Systolic BP - diastolic BP        
(Papers I-III). 
 
Increased pulse pressure 
increases the risk of coronary 
heart disease (37).  
Stroke volume/ 
pulse pressure 
(SV/PP) 
Arterial compliance (Paper I). Reduced SV/PP increases 
the risk of CV events 
independently of LV mass 
index and age (38).   
Ambulatory 
arterial stiffness 
index (AASI) 
Derived from ambulatory BP 
measurements (Paper I).  
Increased AASI is associated 
with CV events and predicts 
CV mortality risk (39,40).  
Pulse wave 
velocity (PWV) 
Measurement of arterial  
stiffness. Applanation 
tonometry and the 
SphygmoCor device (Paper 
II) and the oscillometric 
single- cuff method by 
Arteriograph (Paper III). 
Elevated PWV increases the 
risk of CHD and stroke and 
improves risk prediction of 
future CV events (41,42). 
Augmentation 
index (AIx) and 
aortic BP 
Aortic pulse wave analysis 
and augmented central pulse 
pressure. Applanation 
tonometry and the 
SphygmoCor device (Paper 
II), and the oscillometric 
single-cuff method by 
Arteriograph (Paper III). 
Increased AIx predicts risk of 
CV events independently of 
peripheral BP (43). Central 
aortic BP is better related to 
future CV events compared 
to brachial BP (44). 
Carotid-femoral 
PWV / carotid-
radial PWV 
PWV velocity ratio by 
applanation tonometry and 
the SphygmoCor device 
(Papers II,IV). 
Aortic-brachial stiffness 
mismatch is associated with 
CV mortality in high-risk 
patients (45).  
   7 
Furthermore, impaired skin microvascular reactivity is related to the risk of developing 
coronary heart disease, and is associated with diabetes and with an increased risk in patients 
with an acute coronary syndrome (46,47).  
Circulating biomarkers of vascular function such as the intracellular adhesion molecule 
(ICAM)-1, vascular adhesion molecule (VCAM)-1, and E-selectin reflect endothelial 
activation and the risk of atherosclerotic disease (48,49). In hypertension, there are signs of 
systemic inflammation with elevation of circulating markers of inflammation and endothelial 
activation like interleukin (IL)-6 and ICAM-1 (50). Low-grade systemic inflammation with 
increased high-sensitivity C-reactive protein (hsCRP) seems to promote vascular fibrosis with 
remodeling of the arterial wall causing arterial stiffness (51). Also, cardiac remodeling is 
associated with early signs of fibrosis and cytokine activation, suggesting the importance of 
inflammation in hypertension with LV hypertrophy (52,53). However, the influence of 
inflammation, vascular stiffness, and activation of the vascular endothelium in relation to LV 
hypertrophy and BP is not well studied. 
 
1.6 HYPERTENSION AND ESTIMATION OF CARDIOVASCULAR RISK 
Hypertension is one of several major risk factors for CV morbidity and mortality. Thus, 
hypertension is a major threat to public health and remains the most important risk factor for 
premature mortality worldwide (54). There has been a transition during the last 40 years from 
the highest prevalence of hypertension being seen in high-income countries to the highest 
prevalence being seen in low-income and middle-income countries due to population growth 
and increased population age (55). Improvement of BP control to prevent CV disease is 
therefore warranted.   
Treatment of hypertension is based on lifestyle interventions such as reduced salt intake, 
increased exercise, weight reduction, moderation of alcohol intake, and smoking cessation. 
Most often, however, this is not enough to reach the target BP. Antihypertensive treatment is 
effective, well documented, and reduces CV morbidity and mortality (56). It is of great 
importance to assess global CV risk in each individual in order to determine which actions 
are best suited in order to prevent future CV events. Furthermore, stratification of the 
individual CV risk can be assessed by different risk models – like the European SCORE 
(Systematic coronary risk evaluation) (57) or the American Framingham risk score (58) – in 
order to improve prevention strategies. 
One important component in risk factor assessment is to identify early and often asympto-
matic signs of subclinical target organ damage such as LV hypertrophy, microalbuminuria, 
and white matter lesions in the brain, because these findings motivate intensive treatment. 
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1.7 THE EFFECTS OF ANTIHYPERTENSIVE TREATMENT ON BP AND 
CARDIAC AND VASCULAR STRUCTURE AND FUNCTION 
Central aortic BP provides better risk prediction than peripheral brachial BP (43,44). Some 
data suggest that ACE inhibitors lower aortic BP more than the brachial BP and reduce PWV 
(i.e. aortic stiffness) to a greater extent than other antihypertensive drugs (59,60), but results 
are not consistent (61). Such effects of ACE inhibitors have been proposed to improve CV 
outcome in high-risk patients beyond the effects of BP reduction (62,63). Furthermore, there 
is evidence that antihypertensive treatment with ACE inhibitors or AT1-receptor blockers has 
additional effects beyond BP reduction through the reduction of cardiac fibrosis and 
improvement of LV diastolic function compared to other drug classes (64,65). Taken 
together, both the sympathetic nervous system and the RAAS are central for BP regulation 
and vascular control, and there might be beneficial effects on vascular function beyond BP 
reduction by treatment with drugs that inhibit the RAAS. However, the effects of treatment 
on endothelial function in patients with mild to moderate primary hypertension are unclear 
and the results are often conflicting (66-68). Thus, comparison of treatment with drugs 
blocking the RAAS and other BP-lowering drug classes are warranted. Furthermore, the 
effects of alpha 1-adrenoceptor blockers on endothelial function and indices of aortic stiffness 
are not well studied.  
Endothelial dysfunction is related to CV risk, and endothelial function can be evaluated in 
different vascular beds with different techniques. However, it is still unclear how endothelial 
function in larger conduit arteries is related to findings in smaller resistance arteries and to 
skin microvascular reactivity and coronary microcirculatory function. This interesting 
question needs to be further addressed. 
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2 AIMS 
The overall objective of this project was to obtain greater knowledge about the evaluation of 
arterial structure and function in hypertensive patients. Furthermore, we wished to study the 
effects of antihypertensive treatment on vascular structure and function because this might 
help to individualize antihypertensive treatment in order to reduce future risk of CV disease. 
 
More specifically, we had the following aims: 
1. To study the effects of antihypertensive treatment on arterial stiffness and endothelial 
function. 
2. To study whether blocking the RAAS has effects on arterial stiffness and endothelial 
function beyond BP reduction alone. 
3. To evaluate an oscillometric single cuff-based method to assess central arterial function 
compared to established methods using PWA with applanation tonometry.  
4. To compare several non-invasive physiological methods in the evaluation of endothelial 
function in different vascular beds in humans and their relation to the risk of future CV 
disease.  
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3 MATERIALS AND METHODS 
3.1 DESIGN AND STUDY POPULATION 
This thesis is based on two clinical studies – the “Swedish irbesartan left ventricular 
hypertrophy versus atenolol project”, SILVHIA (Paper I), and the “Doxazosin-ramipril 
study”, DoRa (Papers II–IV). Baseline characteristics of the study populations are presented 
in table 2. 
 
 Table 2.  Baseline characteristics of study populations. 
 
Mean values ± SD. NT, normotensive; HT, hypertension; LVH, left ventricular hypertrophy; LV, left 
ventricular; BP, blood pressure; eGFR, estimated glomerular filtration rate. 
 SILVHIA DoRa 
 NT control  HT no LVH  HT and LVH    
n 38 38 114 71 
Male/female, % 74/26 74/26 67/33 63/37 
Age, yrs. (range) 54 ± 9 (37-75) 54 ± 9 (36-74) 54 ± 9 (31-74) 55 ± 13 (23-76) 
Body mass index 
(kg/m2)  
24.8 ± 2.3 26.6 ± 3.4 27.1 ± 3.4 26.8 ± 4.7 
LV mass index 
(g/m2) 
88 99 149 103 
Systolic BP       
(mm Hg) 
121 ± 10 148 ± 14 162 ± 19 154 ± 10 
Diastolic BP      
(mm Hg) 
78 ± 7 97 ± 6 104 ± 8 93 ± 9 
Heart rate (bpm) 61 ± 7 68 ± 8 68 ± 10 61 ± 8 
Smoking (%) 19 16 24 6 
Cholesterol 
(mmol/L) 
5.8 ± 1.2 5.9 ± 1.0 6.0 ± 1.0 5.4 ± 1.1 
Glucose (mmol/L) 5.1 ± 0.6 5.3 ± 0.5 5.4 ± 2.6 5.4 ± 0.6 
eGFR 
(ml/min/1.73m2) 
87.2 ± 18.0 97 ± 26.5 95 ± 24.8 90.4 ± 14.5 
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3.1.1 Paper I 
The aim of the SILVHIA project was to study the treatment effects of the AT1-receptor 
blocker irbesartan compared to the beta-adrenoceptor blocker atenolol in terms of BP 
reduction, LV geometry, and LV systolic function in patients with hypertension and LV 
hypertrophy (69,70).  
The primary aim in paper I was to study indices of arterial stiffness and markers of 
endothelial function and inflammation in patients with hypertensive heart disease compared 
to hypertensive patients with no LV hypertrophy and compared to normotensive subjects. 
The secondary aim was to compare the effects beyond BP reduction on vascular structure and 
function by blocking the RAAS as compared to blocking the sympathetic nervous system.  
The SILVHIA study included 115 patients with hypertension (diastolic BP 90–115 mm Hg) 
and LV hypertrophy, 38 hypertensive patients with no LV hypertrophy, and 38 normotensive 
controls (diastolic BP <90 mm Hg and a normal LV mass) matched for both age and sex 
(69,70). Exclusion criteria were an ejection fraction <45%, secondary hypertension, renal 
failure, congestive heart failure, and coronary and/or valvular heart disease. All drugs were 
withdrawn and followed by a 4–6 week period of single-blind placebo treatment. Patients 
with hypertension and LV hypertrophy were randomized to double-blind treatment with 
irbesartan (150 mg o.d.) or atenolol (50 mg o.d.). If diastolic BP after 6 weeks was ≥90 mm 
Hg, the study drug dose was doubled. Open-label hydrochlorothiazide and felodipine were 
added if required to achieve a diastolic BP <90 mm Hg. The duration of the study was 48 
weeks. Evaluation of vascular structure and function and biochemical markers of endothelial 
activation and inflammation was performed at baseline and at weeks 12 and 48. The study 
design is presented in figure 3. 
 
 
Figure 3. The SILVHIA study design. HT, hypertension, LVH, Left ventricular hypertrophy; NT, 
normotensive. 
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3.1.2 Papers II–IV 
The primary aim in paper II was to study the effect of antihypertensive therapy on arterial 
stiffness and on endothelial function in patients with mild to moderate primary hypertension. 
The secondary aim was to evaluate the potential effects on vascular structure and function 
beyond BP reduction by blocking the RAAS as compared to blocking the sympathetic 
nervous system. 
The DoRa study was a randomized double-blind parallel group study in 71 patients above 18 
years of age with mild to moderate hypertension. Included patients were previously untreated 
or were randomized after an additional wash-out period of 4 weeks. BP criteria for inclusion 
was an office systolic BP >140 mm Hg and/or diastolic BP >90 mm Hg. Secondary 
hypertension was ruled out by clinical examination and routine screening of blood tests. 
Exclusion criteria were severe hypertension (BP >180/110 mm Hg), structural heart disease, 
congestive heart failure, arrhythmias, diabetes, and hyperlipidaemia. Patients were 
randomized to the alpha 1-adrenergic blocker doxazosin 4 mg or the ACE inhibitor ramipril 5 
mg, with doubling of the dose after two weeks for additional 10 weeks of treatment. A total 
of 61 patients completed the study. The study design is presented in Figure 4. BP 
measurements, study blood samples, vascular investigations of arterial stiffness (applanation 
tonometry and the oscillometric single-cuff method), and assessment of endothelial function 
(FMD, PWA with beta 2-adrenoceptor agonist stimulation, and LDF and iontophoresis) was 
performed at baseline and at 12 weeks, see paper II for details. Vascular examinations were 
performed on two consecutive days to avoid pharmacological interaction of the vascular 
study protocols. Study medication was taken routinely at the same hour by the patients, and at 
week 12 the BP and vascular investigations were performed 2 hours after intake of the study 
medication in order to achieve the maximum pharmacological effects of treatment.  
 
Figure 4. The DoRa study design. 
 
   14 
Paper III was a methodological study comparing applanation tonometry and the SphygmoCor 
device to the oscillometric single-cuff technique by Arteriograph. Simultaneous baseline 
measurements from 71 patients from paper II were compared. Indices of arterial stiffness 
(aortic BP, AIx, and PWV) by both techniques were evaluated. The oscillometric single-cuff 
method was also used to evaluate the effects of treatment on BP reduction and on indices of 
arterial stiffness.  
In paper IV, four different methods (FMD, PWA with beta 2-adrenoceptor agonist 
stimulation, LDF and iontophoresis in skin microcirculation, and coronary microcirculation 
as measured by the SEVR) were used to evaluate the interrelationship of endothelial function 
in different vascular beds. We also studied how endothelial functions in different vascular 
beds were related to CV risk, assessed by SCORE, and to signs of hypertensive heart disease.  
 
3.2 METHODS 
3.2.1 Measurements of BP, vascular compliance, and arterial stiffness 
In paper I, seated systolic and diastolic BP was determined as the average of three 
consecutive measurements using a mercury sphygmomanometer after resting for at least 10 
minutes. In paper II, the systolic and diastolic BP was determined as the average of three 
consecutive measurements taken 1 minute apart after a 10 min rest in supine position using an 
oscillometric device (OMRON 705IT, OMRON Healthcare Co., Ltd. Kyoto Japan). Pulse 
pressure was calculated as the systolic minus diastolic BP (papers I–IV), mean arterial 
pressure was calculated as the diastolic BP + 1/3 × pulse pressure (papers II–III), and arterial 
compliance was measured as the stroke volume divided by pulse pressure (SV/PP) (paper I). 
Ambulatory BP recordings were performed in the SILVHIA project (71), and we used these 
values to calculate the ambulatory arterial stiffness index (AASI) as a measure of arterial 
stiffness. The AASI was obtained by plotting diastolic BP against systolic BP, where AASI is 
defined as 1 minus the regression slope of the diastolic BP to the systolic BP (72).  
Two different methods for evaluation of central aortic BP and indices and arterial stiffness 
were used simultaneously in DoRa – PWA by applanation tonometry and the SphygmoCor 
software and equipment in papers II and III, and the oscillometric single-cuff technique with 
the Arteriograph in paper III.  
PWA was assessed by applanation tonometry (Millar Instruments, Houston, TX, US), and the 
SphygmoCor device (AtCor Pty Ltd, West Ryde, NSW, Australia). The central aortic 
waveform was calculated from radial applanation tonometry using a general transfer function 
by the device software, and central BP was derived. The carotid-femoral PWV was calculated 
as the carotid-to-femoral distance divided by the transit time difference of the carotid and 
femoral pulse wave propagation (24). The carotid-radial PWV was calculated similarly in 
order to obtain the carotid-femoral/carotid-radial PWV ratio, which is a measure of the aortic-
brachial mismatch (45).  
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The oscillometric cuff-based method (Arteriograph, TensioMed Kft, Budapest, Hungary) 
uses a single-arm cuff device, and the brachial systolic and diastolic BP is measured by 
automatic inflation of the cuff. The pressure change during suprasystolic BP (>35 mm Hg 
above peak systolic value) is driven to the device by the hose from the cuff and is 
subsequently recorded by a piezoelectric sensor. The approximate time difference of the first 
systolic peak (the ejection of blood from the left ventricle to the aorta) and the second peak 
(the retrograde reflected pulse wave from the iliac bifurcation) represents the return time. 
PWV was calculated by dividing the traveled distance (the tapered jugulum to the symphysis 
distance) by the return time / 2. AIx was calculated as 100 × (second – first systolic wave) / 
pulse pressure. Aortic BP was obtained by an algorithm in the software based on invasively 
measured aortic BP (27).  
 
3.2.2 Functional methods to evaluate endothelial function 
A summary of methods to evaluate endothelial function in different vascular beds is 
presented in Table 3. 
FMD was measured by post-ischemic hyperaemia in the non-dominant arm. The resting basal 
diameter of the brachial artery was measured for 1 minute by a Vivid 7 Dimension ultrasound 
device with a 9 MHz linear transducer (GE Medical System, Horten, Norway). Thereafter, an 
inflated pneumatic tourniquet placed around the forearm to a pressure of 250 mm Hg for 5 
minutes induced occlusion of the brachial artery. After cuff deflation, the maximum change 
in diameter was achieved by repeated measurements (30, 60, and 90 s). The relative change 
from baseline diameter was taken as a measure of FMD. Finally, after 10 min of additional 
rest, EIDV was induced by 0.4 mg sublingual glyceryl trinitrate (GTN) (Nitrolingual, G Pohl-
Boskamp GmbH & Co KG, Hohenlockstedt, Germany). Relative changes in artery diameter 
were calculated from rest to 4 min following GTN administration (15). In addition, the 
endothelial function index (EFI), i.e. FMD/GTN ratio, was used to improve the validation of 
the EDV in relation to the EIDV, as reported elsewhere (73). 
EDV was also evaluated by applanation tonometry and PWA with beta 2-adrenoceptor 
agonist stimulation. PWA was performed before and 15 and 20 min after 0.25 mg sc 
terbutaline (Bricanyl, AstraZeneca, Mölndal, Sweden) to evaluate the maximum effect of 
beta 2-adrenoceptor agonist stimulation. Aortic waveforms were generated by the 
SphygmoCor software from radial artery applanation tonometry. This receptor-mediated 
mechanism represents EDV in the resistance arteries. The reflection index (RI) is defined as 
the relative height of the first diastolic reflective pulse wave in relation to the first systolic 
peak, as presented in Figure 5 (17). A smaller relative change after beta 2-adrenoceptor 
agonist stimulation is associated with impaired endothelial function. Also, the relative change 
in radial AIx and aortic AIx can be an alternative way to measure wave reflection by this 
technique (16).  Another method is photoplethysmography and digital volume pulse, as 
described by others (74).  
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Figure 5. Pulse wave analysis with applanation tonometry of the radial artery. 0,onset of systole; a,  
peak systole; b,reflected wave in systole; c, dicrotic notch; d, reflected wave in diastole. Modified from 
(17).  
 
3.2.3 Evaluation of skin microcirculation 
Forearm skin microvascular reactivity (vasodilatation) was assessed by LDF and 60 s 
transcutaneous iontophoretic administration (Periflux system 5000, PF 5010 LDPM Unit, 
PF5010 Temp Unit, and 481-1 Single Probe, Perimed, Järfälla, Sweden) of small amounts of 
Ach (Sigma-Aldrich AB, Stockholm, Sweden) and SNP (Hospira, Inc., Lake Forest, IL, 
USA) to represent EDV and EIDV, respectively (18). Skin microvascular peak flux was 
recorded continuously up to 16 min after iontophoresis and was expressed in arbitrary units. 
To determine maximum skin microvascular hyperaemia, peak flux was evaluated after local 
heating of the forearm skin to 44°C for 6 min. Heat-induced maximum hyperaemia after local 
heating gives information about the total microvascular reactivity, and the maximum skin 
hyperaemia seems to be enhanced by NO (19). Reduced maximum hyperaemia is an 
indicator of increased CV risk in diabetic patients with acute coronary syndrome (47), and 
statin treatment improves maximum hyperemia in patients with coronary artery disease and 
hyperglycaemia (75). 
 
3.2.4 Evaluation of coronary microcirculation  
The SEVR was calculated by PWA and the aortic pulse waveform using the SphygmoCor 
device in paper IV. The SEVR is an indirect measure of subendocardial perfusion capacity 
and is an index of oxygen supply and demand of the myocardium (21). It was calculated as 
the systolic to diastolic pressure time integral. The SEVR is associated with coronary flow 
reserve, which is a measure of coronary microcirculation (20), and it is associated with CV 
risk and can be used to improve risk prediction in high-risk patients (76,77).  
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Table 3. Methods to measure macrovascular endothelial function and microvascular reactivity in 
different vascular beds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FMD, flow mediated vasodilation; GTN, glyceryl trinitrate; PWA, pulse wave analysis; LDF, laser 
Doppler fluxmetry; SEVR, subendocardial viability ratio; EDV, endothelium-dependent 
vasodilation; EIDV, endothelium-independent vasodilation  
 
 
3.2.5 Echocardiography  
Echocardiography was performed by standard procedures in the supine position. 
Measurements of LV dimensions and wall thickness were made using the M-mode technique. 
The Penn convention was used for calculation of LV mass (78), which was corrected for 
body surface area, i.e. the LV mass index. LV hypertrophy was defined as a LV mass index 
>131 g/m2 and  >100 g/m2 (paper I) and >115 g/m2 and >95 g/m2 (paper IV) for men and 
women, respectively, reflecting changes in guideline recommendations over time. Relative 
wall thickness was calculated as (interventricular septum thickness + posterior wall thickness) 
/ LV end diastolic diameter, and it was considered increased if  >0.45 (paper I) or >0.42 
(paper IV). LV volumes in systole and diastole were calculated from area tracings using the 
disc summation method (modified Simpson's rule) to calculate stroke volume (paper I).  
Evaluation of diastolic function was made by pulsed Doppler registrations. The mitral peak 
flow velocities of the early (E) and late (A) waves were used for the E/A ratio calculations. 
Method Mechanism Vascular bed 
FMD Post-ischemic reactive hyperemia. 
Shear stress. EDV (Papers II, IV) 
Conduit arteries (15) 
GTN-mediated 
vasodilation  
NO donor mediates relaxation of 
smooth muscle cells. EIDV (papers II, 
IV) 
Conduit arteries (15) 
PWA and beta 2-
adrenoceptor agonist 
stimulation 
Receptor-mediated stimulation. EDV. 
Change in the reflective pulse wave 
form (papers II, IV) 
Resistance arteries 
(16) 
Iontophoresis and LDF Acetylcholine-mediated EDV and 
sodium nitroprusside-mediated EIDV 
vasodilatation (papers II, IV) 
Forearm skin 
microcirculation (18) 
Local heating Maximum reactive hyperaemia 
(papers II, IV). 
Forearm skin 
microcirculation (19) 
SEVR Indirect measurement of coronary 
microcirculation, calculated from PWA 
and the SphygmoCor (paper IV) 
Coronary    
microcirculation (20) 
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Tissue Doppler echocardiography was performed in the apical four-chamber view, and 
pulsed wave Doppler was used to register the mitral annular systolic (s´) and early diastolic 
(e´) velocities. Calculation of the e´ mean (mean of the e´ septal and e´ lateral registrations) 
was used to assess the LV diastolic filling pressure, E/é. The left atrial volume was also 
measured as a diastolic parameter. For methodological details and reproducibility, see 
elsewhere (69,79). 
 
3.2.6 Assessment of global cardiovascular risk by SCORE 
The SCORE algorithm (57) was used to predict CV risk in patients (paper IV). SCORE is 
calculated by adding information on age, sex, smoking, systolic BP, and total cholesterol to 
predict the 10-year risk for CV mortality. (57). For better risk prediction, a web-based 
calculator was used with high-density lipoprotein included in the model as recommended in 
current guidelines (80). 
 
3.2.7 Circulating biomarkers of endothelial activation and inflammation  
Blood samples were obtained under fasting conditions from an antecubital vein after 20 
minutes of supine rest by blood collection needles into Vacutainer tubes on ice. Following 
centrifugation (+4°C, 1500 × g for 15 min), plasma and serum were frozen immediately at 
−70°C. Routine biochemistry was performed following standard procedures. 
In paper I, serum concentrations of hsCRP were immunologically measured in plasma (Dade 
Behring, Marburg, Germany), and serum concentrations of IL-6 were measured with the 
enzyme-linked immunosorbent assay technique (Novakemi AB, Stockholm, Sweden). E-
selectin, ICAM-1 and VCAM-1 were measured by enzyme immunoassays (R&D systems, 
Abingdon, UK). In paper II, ICAM-3, IL-6, IL-8, hsCRP, tumor necrosis factor-α, and 
monocyte chemoattractant protein-1 were measured by assays from MesoScale Diagnostics 
(Human Cytokine Assay, Ultra-Sensitive Kit, MSD, Bethesda, USA).  
 
3.3 STATISTICAL ANALYSIS 
Data are presented as mean values ± SD (or SEM for calculated differences) or as medians 
and interquartile ranges. Skewed variables were log transformed. Group comparisons were 
made by the analysis of variance or by multivariate analysis of variance. Multiple linear 
regression analysis was used to assess the effects of treatment in papers I–IV. Pearson’s 
correlation coefficient (r) was used to study markers of inflammation, endothelial activation 
and arterial function in relation to BP and LV hypertrophy (paper I), to study the relationship 
between the oscillometric single-cuff method by Arteriograph and the applanation tonometry 
method by SphygmoCor (paper III) and to study the relationship between endothelial 
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functional measurements and CV risk assessed by SCORE (paper IV). In addition to the 
linear regression model, Bland-Altman agreement analysis was used in paper III. In paper IV, 
associations with CV risk, as assessed by SCORE, were also assessed in a multivariable 
logistic regression model, including PWV and microalbuminuria, to improve CV risk 
prediction, as compared to SCORE alone (81,82). 
The primary outcome in the SILVHIA study was to evaluate the reduction of LV mass by 
treatment with irbesartan and atenolol. A sample size of 48 patients per treatment group was 
selected to detect a difference of LV mass index from week 0 to 24 of 7.9 g/m2 between 
groups, with 2 alpha 0.05 and beta 0.90. To allow for a dropout rate of 15%, 115 subjects 
were included (69).  
The two co-primary outcomes in paper II were change in endothelial function, as assessed by 
flow-mediated vasodilatation, and change in hemostatic function, as measured by the 
generation of thrombin–antithrombin complex. To determine the size of the study population, 
assuming 2 alpha 0.05 and beta 0.80, we a priori calculated 2 × 24 subjects as sufficient to 
detect a 0.6% difference between the two study groups in flow-mediated vasodilatation by 
treatment, and 2 × 26 subjects as sufficient to detect a 0.4 µg/L difference in thrombin–
antithrombin complex by treatment between the two groups (paper II). All statistical tests 
were 2-sided and carried out to a significance level P of <0.05.  
 
3.4 ETHICAL CONSIDERATIONS 
All studies were conducted in accordance with the Declaration of Helsinki and were 
approved by the Regional Ethics Committee in Stockholm. All participants gave their oral 
and written informed consent.  
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4 RESULTS 
4.1 ARTERIAL STIFFNESS AND INFLAMMATION IN RELATION TO 
HYPERTENSION-INDUCED HEART DISEASE AND BP (PAPER I) 
Patients with hypertension and LV hypertrophy had higher baseline BP compared with 
hypertensive patients with no LV hypertrophy (Table 2). The measures of metabolic status 
and kidney function were similar between the groups. Hypertensive subjects showed 
increased arterial stiffness compared to controls, and patients with hypertension and LV 
hypertrophy showed signs of increased arterial stiffness compared to hypertensive patients 
without LV hypertrophy and compared to controls. Furthermore, they also showed increased 
levels of inflammatory markers (hsCRP and IL-6), as presented in Figure 6. Levels of 
endothelial markers and leukocyte counts were similar in the normotensive controls and the 
hypertensive groups. Arterial stiffness was independently related to mean arterial BP and LV 
mass, and the AASI was independently related to mean arterial BP and hsCRP but not to  
 
Figure 6. All data are presented as mean values ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001. NT, 
normotensive controls; HT, hypertension; LVH, left ventricular hypertrophy; AASI, ambulatory arterial 
stiffness index, SV/PP, stroke volume/pulse pressure; PP, pulse pressure; hs-CRP, high-sensitivity C-
reactive protein; IL-6, interleukin-6. From paper I. 
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endothelial adhesion molecules. Thus, hypertensive subjects also had signs of subclinical 
inflammation that were elevated with more pronounced hypertension and increased LV mass. 
Endothelial functional markers were similar comparing groups, and there were no relations 
between endothelial markers and BP or LV mass.  
 
4.2 THE EFFECTS OF TREATMENT ON INDICES OF ARTERIAL STIFFNESS 
AND ENDOTHELIAL FUNCTION (PAPERS I AND II) 
In paper I, BP reduction was similar in the irbesartan and atenolol groups, but reduction of LV 
mass was greater in the irbesartan group, as previously reported (69). Treatment had no effect 
on the AASI, and there were no differences when comparing treatment groups (Figure 7 a). 
Arterial compliance (SV/PP) was improved in both treatments groups, and SV/PP was  
 
 
Figure 7. The effects of treatment with irbesartan (n = 35–54) and atenolol (n = 42–57) Mean values 
and SD. Multivariate analysis of variance, adjusted for treatment group. AASI, ambulatory arterial 
stiffness index, SV/PP, stroke volume/pulse pressure; PP, pulse pressure. From paper I 
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improved to a greater extent by atenolol, as compared to irbesartan. The greater reduction in 
heart rate (increasing stroke volume) by atenolol might be an explaining factor to this finding 
(Figure 7 b). Pulse pressure was reduced by both irbesartan and atenolol, with a larger 
reduction by the AT1-receptor blocker than by the beta adrenoceptor-blocker (Figure 7 c).  
In paper II, the brachial and aortic BP was reduced by both treatments, with a larger reduction 
for ramipril, as compared to doxazosin. Central aortic BP was reduced more than brachial BP, 
with no differences between treatment groups. The carotid-femoral PWV and carotid-radial 
PWV was reduced by ramipril, as compared to doxazosin. AIx was reduced by both 
treatments, but there were no significant differences between treatments. 
Relative changes comparing treatments are presented in Figure 8, which corresponds to the 
absolute values presented in Table 4.  
 
 
Figure 8. Relative changes (mean values ± SEM) in BP and vascular function by treatment. Significant 
treatment-induced changes between groups are shown as *P < 0.05. SBP, systolic blood pressure; br, 
brachial; ao, aortic; DBP, diastolic blood pressure; PWV, pulse wave velocity; car-fem, carotid-femoral; 
car-rad, carotid-radial; AIx, augmentation index. From paper II. 
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Table 4. Treatment effects on BP and indices of arterial stiffness (paper II) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean values ± SD at week 0 and 12 for 27–33 subjects in each treatment group, including all subjects 
with valid measurements at week 0 or 12. P denotes significant changes by repeated measured 
MANOVA. For SBP, systolic blood pressure; br, brachial; ao, aortic; DBP, diastolic blood pressure; 
PWV, pulse wave velocity; car-fem, carotid-femoral; car-rad, carotid-radial; AIx, augmentation index.  
 Week Doxazosin Ramipril p-value by repeated 
measures MANOVA 
SBP br (mm Hg) 0 148.0 ± 11.0 148.3 ± 16.3 time <0.001 
 12 142.3 ± 12.1 136.2 ± 11.6 group 0.27 
    time x group 0.030 
SBP ao (mm Hg) 0 140.3 ± 12.9 139.2 ± 15.8 time <0.001 
 12 131.7 ± 14.8 124.7 ± 13.3 group 0.19 
    time x group 0.039 
DBP br (mm Hg) 0 89.0 ± 10.3 88.0 ± 8.1 time <0.001 
 12 84.6 ± 10.3 80.1 ± 8.7 group 0.21 
    time x group 0.073 
DBP ao (mm Hg) 0 90.9 ± 10.0 87.8 ± 7.5 time <0.001 
 12 85.2 ± 10.5 80.8 ± 7.1 group 0.058 
    time x group 0.35 
Heart rate  (bpm) 0 58.9  ± 7.6 61.9 ± 8.1 time 0.79 
 12 58.8 ± 9.7 61.3 ± 7.4 group 0.14 
    time x group 0.90 
PWV car-fem (m/s) 0 8.5 ± 1.5 8.9 ± 2.0 time 0.070 
 12 8.3 ± 1.7 8.4 ± 1.9 group 0.42 
    time x group 0.037 
PWV car-rad (m/s) 0 8.7 ± 1.5 9.1 ± 1.0 time 0.38 
 12 8.7 ± 1.2 8.4 ± 1.1 group 0.43 
    time x group 0.034 
AIx (%) 0 29.3 ± 10.4 30.7 ± 13.6 time 0.37 
 12 27.1 ± 11.4 26.8 ± 12.1 group 0.78 
    time x group 0.37 
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In paper II, there were small effects of treatment on endothelial function as evaluated with 
FMD, GTN-mediated vasodilation and PWA, and change of RI, but no difference was seen 
between treatment groups as presented in Table 5. In addition, skin microcirculation – as 
assessed by LDF and iontophoresis – and heat-induced maximum hyperaemia remained 
unchanged by treatment.  
 
Table 5. Assessment of endothelial function by treatment (Paper II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean values ± SD for relative changes before and following drug treatment, and absolute changes by 
treatment (∆, mean values ± SEM); 23-32 subjects in each treatment group. P-values for the 
differences calculated by repeated measures MANOVA, adjusted for age. FMD, flow mediated 
vasodilation; GTN, glyceryl trinitrate; EFI, endothelial functional index; RI, reflection index.  
 
 
 
 
 Week Doxazosin Ramipril p-value by repeated 
measures MANOVA 
FMD (%) 0 6.3 ± 4.4 5.3 ± 4.2 time 0.34 
 12 5.5  ± 3.1 4.5 ± 4.3 group 0.75 
  Δ 0-12 −0.3 ± 1.0 −1.1 ± 1.0 time x group 0.57 
GTN (%) 0 15.5 ± 6.8 14.4 ± 7.0 time 0.92 
 12 14.4 ± 7.0 14.4 ± 6.9 group 0.97 
  Δ 0-12 −0.5 ± 1.3 0.3 ± 1.3 time x group 0.67 
EFI 0 0.47 ± 0.38 0.49 ± 0.56 time 0.98 
 12 0.51 ± 0.41 0.44 ± 0.64 group 0.90 
  Δ 0-12 0.07 ± 0.12 0.07 ± 0.12 time x group 0.42 
RI (%) 0 −7.3 ± 2.8 −6.8 ± 3.2 time 0.68 
 12 −6.6 ± 3.1 −7.7 ± 3.8 group 0.54 
  Δ 0-12 0.3 ± 0.9 −0.8 ± 1.0 time x group 0.43 
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4.3 THE EFFECTS OF TREATMENT ON CIRCULATING ENDOTHELIAL AND 
INFLAMMATORY MARKERS (PAPERS I AND II) 
In SILVHIA, there were small effects of treatment on circulating endothelial and 
inflammatory markers (paper I). Table 6 presents the results of treatment on circulating 
endothelial and inflammatory markers from SILVHIA during the initial 12 weeks with single 
drug therapy with irbesartan and atenolol (paper I) and from DoRa with ramipril or doxazosin 
under similar conditions (83). Taken together, there were no clear effects from blocking the 
RAAS on circulating endothelial and inflammatory markers compared to treatment with 
atenolol or doxazosin. It is important to note, however, that the biomarkers that were assessed 
and the analytical procedures that were used were somewhat different between the two studies.  
 
4.4 EVALUATION OF A SINGLE-ARM OSCILLOMETRIC CUFF METHOD IN 
COMPARISON TO PWA WITH APPLANATION TONOMETRY (PAPER III) 
First, we compared measures of indices of arterial stiffness by the oscillometric single-cuff 
method with the Arteriograph device to PWA by applanation tonometry by the SphygmoCor 
device. Baseline measurements of BP and indices of arterial stiffness are presented in Figure 
9. As shown, the methods were closely related. However, the oscillometric cuff-based method 
recorded higher values as shown in the corresponding Bland-Altman analysis of mean 
differences (Figure 9). The relation for PWV values was weaker, but significant. This suggests 
that PWV measurements estimated with the oscillometric cuff method and those estimated by 
PWA with applanation tonometry are related but might not be interchangeable.  
Second, the effects of treatment on central aortic BP and indices of arterial stiffness were 
evaluated in 58 patients at baseline who completed the study period of 12 weeks. At baseline, 
office BP values were, 151 ± 8/93 ± 10 mm Hg and 155 ± 9/93 ± 7 mm Hg for the doxazosin 
and ramipril groups, respectively. Treatment reduced brachial and aortic BP as assessed by the 
oscillometric cuff method, and reductions in both brachial and aortic BP were greater for 
ramipril compared to doxazosin. Treatment reduced the aortic systolic BP more than the 
brachial systolic BP, and this effect was greater in the ramipril group compared to the 
doxazosin group. Treatment improved the AIx in both treatments groups. By univariate 
analysis, this change in AIx was shown to be greater in the ramipril group compared to the 
doxazosin group. However, when adjusting for potential confounders this difference was 
weakened. Both doxazosin and ramipril reduced PWV and increased the transit time, with no 
significant differences between treatments. To conclude, the oscillometric single-cuff method 
was suitable for detecting treatment-induced changes in BP values and indices of arterial 
stiffness.  
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Table 6. Circulating endothelial markers and inflammatory markers in papers I and II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median and interquartile range. Multivariate analysis of variance adjusted for study drug 
treatment and smoking. From (83) and unpublished data. ICAM-1, intracellular adhesion 
molecule-1; VCAM-1, vascular adhesion molecule-1; hsCRP, high sensitive C-reactive protein, 
IL-6, interleukin 6; IL-8, interleukin 8, TNF- α, tumor necrosis factor-α, MCP-1, monocyte 
chemoattractant protein-1.  
SILVHIA Irbesartan Atenolol   
Week 0 12 0 12 P (time) P (time x 
group) 
E-selectin 
(ng/ml) 
48 [37;59] 48 [40;62] 42 [34;57] 39 [31;55] 0.029 0.031 
ICAM-1 
(ng/ml) 
227 
[191;256] 
228 
[200;259] 
229 
[194;272] 
216 
[191;272] 
0.79 0.047 
VCAM-1 
(ng/ml) 
613 
[522;841] 
603 
[473;728] 
613 
[528;744] 
654 
[532;745] 
0.81 0.08 
hsCRP 
(mg/l) 
1.7 [1.0;2.4] 1.2 [0.8;2.6] 1.3 [0.9;4.1] 1.4 [0.7;2.9] 0.03 0.08 
IL-6 (ng/l) 2.2 [1.7;3.2] 2.4 [1.5;3.1] 1.9 [1.4;2.8] 1.9 [1.5;3.1] 0.64 0.24 
DoRa Ramipril Doxazosin   
Week 0 12 0 12 P (time) P (time x 
group) 
E-selectin 
(ng/ml) 
2.7 [1.5;4.0] 2.6 [1.7;5.1] 2.9 [1.8;4.0] 2.5 [1.7;3.7] 0.92 0.14 
P-selectin 
(ng/ml) 
14.1 
[10.8;18;.9] 
14.9 
[10.8;22.0] 
16.6 
[12.1;20.9] 
14.2 
[10.9;18.1] 
0.71 0.15 
ICAM-3 
(ng/ml) 
0.4 [0.3;0.6] 0.5 [0.2;0.6] 0.5 [0.3;0.6] 0.4 [0.3;0.5] 0.60 0.56 
hsCRP 
(mg/l) 
1.3 [0.7;2.1] 1.4 [0.7;2.7] 1.8 [1.2;3.0] 1.4 [0.9;2.3] 0.52 0.11 
IL-6 
(pg/ml) 
0.3 [0.2;0.4] 0.4 [0.2;0.5] 0.3 [0.2;0.4] 0.3 [0.2;0.4] 0.78 0.012 
IL-8 
(pg/ml) 
1.9 [1.3;0.4] 1.7 [1.3;2.0] 1.8 [1.5;2.2] 1.5 [1.2;1.8] 0.13 0.69 
TNF-α 
(pg/ml) 
1.0 [0.8;1.1] 1.3 [0.8;1.2] 1.0 [0.8;1.2] 0.9 [0.8;1.1] 0.41 0.81 
MCP-1 
(pg/ml) 
42 [37;48] 41 [35;43] 42 [34;51] 42 [36;52] 0.14 0.90 
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Figure 9. Comparison of the oscillometric single-cuff method and PWA with applanation tonometry. 
Pearson´s correlation coefficients and Bland-Altman agreement analysis of the difference in mean 
values for (a-b) systolic aortic BP (SBP), (c-d) aortic pulse pressure (PP), (e-f) augmentation index 
(AIx), and (g-h) pulse wave velocity (PWV). From paper III. 
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4.5 ENDOTHELIAL FUNCTION AND MICROVASCULAR REACTIVITY IN 
RELATION TO CV RISK, AS ASSESSED BY SCORE, AND TO 
HYPERTENSION-INDUCED HEART DISEASE (PAPER IV) 
Our results showed that endothelial function in conduit arteries, as assessed by FMD, and the 
EFI were inversely related to SCORE (Figure 10). EIDV was not related to SCORE, and the 
change in RI was not related to SCORE. SEVR was not related to SCORE (Figure 11). Skin 
microcirculation was assessed by LDF and iontophoresis, and maximum skin-reactive 
hyperemia was evaluated by local heating. The relative change in peak flux after Ach 
iontophoresis was not related to SCORE, but both the EIDV relative change in peak flux and 
the heat-induced maximal hyperemia were inversely related to SCORE (figure 11). 
 
 
 
Figure 10. The relations between (a) flow-mediated vasodilatation (FMD), (b) glyceryl trinitrate (GTN)-
mediated vasodilation, (c) endothelial functional index (EFI), and (d) relative change in reflection index 
(RI) before and after beta 2-adrenoceptor agonist stimulation, and the 10-year risk for a fatal cardio-
vascular event as assessed by the systematic coronary risk evaluation (SCORE). From paper IV. 
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Figure 11. The relations between (a) the subendocardial viability ratio (SEVR), (b) the relative change 
in endothelial-dependent peak flux (Δ % Peak flux Ach), (c) the relative change in endothelial-
independent peak flux (Δ % Peak flux SNP), and (d) the relative change in the peak flux after heat-
induced maximal hyperemia (Δ % Peak flux heat) and the 10-year risk for a fatal cardiovascular event 
as assessed by the systematic coronary risk evaluation (SCORE). From paper IV. 
 
FMD was not related to LV mass, and there were no relations between FMD and diastolic 
parameters (i.e. relative wall thickness, E/A, E/e´, or left arterial size). The EFI tended to be 
inversely related to the left arterial volume, but no other diastolic measures approached 
significance. The SEVR tended to be improved by reduced filling pressures, E/é, but the 
change in RI and the skin microcirculation were not related to LV mass index or diastolic 
function. FMD tended to be related to the aortic pulse pressure, and the SEVR was inversely 
related to aortic pulse pressure (Figure 12 a-b). Both FMD and the SEVR were inversely 
related to PWV (Figure 12 c-d). GTN-mediated vasodilation, EFI, and the change in RI were 
not related to PWV or aortic pulse pressure. In skin microcirculation, both the Ach peak flux 
and the peak flux after heat-induced maximal hyperemia were related to the carotid-femoral 
PWV / carotid-radial PWV ratio (Figure 12 e-f). The SNP-induced peak flux was not related 
to the PWV ratio. 
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Figure 12. The relations between (a) flow mediated vasodilataion (FMD), (b) the subendocardial 
viability ratio (SEVR), and aortic pulse pressure, (c) FMD, (d) SEVR, and carotid femoral pulse wave 
velocity (car-fem PWV), (e) Acetylcholine mediated peak flux (Ach peak flux), (f) heat induced peak flux 
(Heat peak flux), and the carotid-femoral to carotid-radial pulse wave velocity ratio (car-fem PWV / car-
rad PWV). From paper IV. 
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4.6 COMPARISON OF METHODS TO EVALUATE INDICES OF ENDOTHELIAL 
FUNCTION IN DIFFERENT VASCULAR BEDS (PAPER IV) 
Methods representing different vascular beds were poorly interrelated. Thus, endothelial 
function in the conduit arteries as assessed by FMD did not relate to the RI change, the SEVR, 
or the skin microcirculation. GTN-mediated vasodilation tended to be related to the RI change 
and tended to be inversely related to the skin microcirculatory response to the Ach peak flux. 
The EFI tended to be related to the SEVR. There was a trend for the RI change to be inversely 
related to the skin microcirculatory response to the Ach peak flux, and the RI change was 
inversely related to the Ach mediated relative peak flux change. This means that a larger 
reduction of RI after beta 2-adrenoceptor agonist stimulation – which indicates improved 
endothelial function in the resistance arteries – is related to skin microvascular endothelial 
function. Interestingly, there were no relations between coronary microcirculation and skin 
microcirculation.  
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5 GENERAL DISCUSSION 
5.1 THE RELATIONS BETWEEN BP, ARTERIAL STIFFNESS, 
INFLAMMATION, AND HYPERTENSION-INDUCED HEART DISEASE 
Patients with hypertension show signs of increased systemic inflammation (84,85) and 
increased arterial stiffness (51), and our results showed that both were independently related 
to BP (paper I). In patients with hypertension-induced LV hypertrophy, these signs of 
inflammation and increased arterial stiffness are more pronounced. These results suggest that 
arterial stiffness contributes to an increase in LV mass beyond the effects of elevated BP. In 
contrast, circulating markers of endothelial activation were not related to BP or LV mass. 
Thus, endothelial activation appears to be less prominent in patients with uncomplicated 
hypertension, as compared to subjects with established atherosclerotic disease.  
 
5.2 THE EFFECT OF ANTIHYPERTENSIVE TREAMENT ON VASCULAR 
STUCTURE AND FUNCTION  
Our results in papers I–III showed that antihypertensive treatment with different drug classes 
to lower BP also reduces arterial stiffness. The effects of treatment on BP and the indices of 
arterial stiffness in the SILVHIA and DoRa trials are summarized in Table 7. Furthermore, 
the prevailing evidence that inhibition of the RAAS has additional effects on vascular 
structure and function beyond BP reduction is supported by the current results. Thus, there 
was a greater reduction in pulse pressure by an AT1-receptor blocker, as compared to a beta-
adrenoceptor blocker, and the effects on blood pressure and arterial stiffness were related to 
the degree of activation of the RAAS (paper I). Also, the reductions in central aortic BP, 
PWV, and AIx were greater with an ACE inhibitor, as compared to an alpha-adrenoceptor 
blocker (papers II and III), suggesting that both aortic stiffness and resistance vessels were 
affected by the treatment.  
The effects of AT1-receptor blockers are mediated by blocking ANG II-induced stimulation 
of AT1-receptors. The interrupted negative feedback by AT1-receptor blockers on ANG II 
formation will increase the concentrations of ANG II, and this will stimulate AT2- receptors 
and reduce vasoconstriction, hypertrophy, and vascular inflammation. AT1-receptor blockers 
thus seem to have additional effects on vascular structure and function beyond their BP-
lowering effect (86,87). However, the relative contribution of AT1- and AT2-receptor-
mediated effects to this reduction in BP cannot be evaluated with the present results. 
Furthermore, ACE inhibitors also seem to have beneficial effects beyond BP reduction 
(60,61), and they have been shown to reduce aortic stiffness and wave reflection more than 
beta-adrenoceptor blockers, and to reduce central BP more than other drug classes (59,88). 
This remodeling process by ACE inhibitors to reduce arterial stiffness and to increase NO 
availability appears to be dose-dependent (89,90). ACE inhibitors also block bradykinin 
inactivation, and bradykinin is a strong stimulus for NO release that induces NO-mediated  
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Table 7. Effects of antihypertensive treatment by blocking the RAAS versus blocking the 
sympathetic nervous system on blood pressure and indices of arterial stiffness 
SBP, systolic blood pressure; brach, brachial; DBP, diastolic blood pressure, HR, heart rate; PP, 
pulse pressure; SV, stroke volume; AASI, ambulatory arterial stiffness index; PWV, pulse wave 
velocity; AIx, augmentation index. 
 
vasodilation in muscular arteries. These effects through bradykinin might also contribute to 
the beneficial effects of ACE inhibitors in preventing CV events in high-risk patients (62,63).  
Endothelial function was evaluated by different techniques in several different vascular beds, 
and no effects of antihypertensive treatment were seen on endothelial function (paper II). 
Also, there were no differences between treatments with ramipril and doxazosin. Our results 
 SILVHIA (paper I) DoRa (paper II) 
 AT1-receptor 
blocker  
Beta-
adrenoceptor 
blocker 
ACE inhibitor Alpha-
adrenoceptor 
blocker 
SBP brach êê êê êêê êê 
DBP brach êê êê êê êê 
SBP aortic   êêê êê 
DBP aortic   êê êê 
HR ê êêê è è 
PP brach êêê êê êêê ê 
PP aortic   êêê ê 
SV/PP éé ééé   
AASI ê ê   
PWV   êêê êê 
AIx   êê êê 
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are in agreement with others showing only small effects of ACE inhibition on endothelial 
function, as evaluated by FMD (91). Further circumstantial support for these findings was 
provided by the results of circulating markers of endothelial activation that showed only 
minor effects on these markers by treatment (paper I, Table 6). Our results are in agreement 
with others showing small effects on circulating endothelial and inflammatory markers in 
hypertensive patients (92,93). Thus, blocking the RAAS has no significant effect on 
circulating endothelial biomarkers in patients with mild-to-moderate hypertension and no 
signs of atherosclerotic disease.  
In conclusion, antihypertensive treatment improves vascular structure and function. This 
suggests that antihypertensive treatment to achieve target BP is important in order to reduce 
vascular abnormalities and to maintain normal vascular function. Blocking the RAAS has 
additional effects beyond BP reduction on indices of arterial stiffness. Treatment might have 
little effect on systemic inflammation or endothelial activation in hypertensive subjects with 
no overt atherosclerotic disease, although beneficial effects might be observed in patients 
with established atherosclerotic disease.  
 
5.3 THE EVALUATION OF AN OSCILLOMETRIC SINGLE-CUFF METHOD 
COMPARED TO PWA WITH APPLANATION TONOMETRY 
An oscillometric single-arm cuff method  (Arteriograph) was compared to PWA with 
applanation tonometry (SphygmoCor) (paper III). Simultaneously measured values of aortic 
BP, aortic pulse pressure, and AIx were closely related with the two devices, while values of 
estimated PWV were more weakly related, but still significant. These two methods are based 
on different technologies to measure central BP and indices of arterial stiffness. PWA by 
radial applanation tonometry with the SphygmoCor uses a general transfer function in the 
software of the device to recalibrate the radial pulse waveform to the aortic waveform. 
Furthermore, BP from the brachial artery is used for this recalculation of aortic BP, but this 
causes a systematic error with an underestimation of the aortic systolic BP and an 
overestimation of the aortic diastolic BP compared to invasive BP measurements (94). This 
error can be corrected with calibrations, as discussed by others (95-97). Also, the estimated 
AIx seems to be underestimated due to underestimated measurements of aortic BP.  In 
contrast, the oscillometric cuff method measures brachial BP, and it detects pulse wave 
propagation in the aortic arch and large arteries. The calculation of aortic BP is based on the 
reflected late systolic wave, and it shows agreement with invasive aortic systolic BP 
recordings (98). PWV is also obtained differently with the two methods. PWV by applanation 
tonometry is based on several pulse wave registrations, where the variation of the 
isovolumetric contraction time over time can influences the results. The oscillometric cuff 
method uses a single pulse wave registration and the transit time of the returning pulse wave 
from the aortic bifurcation. It has been argued that PWV estimated by the oscillometric 
single-cuff device might be dependent on stiffness from the brachial artery and the fact that 
the reflecting pulse wave is originating from the branching of the subclavian artery from the 
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aorta (99). However, these assumptions are based on a mathematical model, and there is no in 
vivo data supporting these results (100). 
In addition, the ability of the oscillometric single-cuff method to assess effects of treatment 
on BP and indices of arterial stiffness was evaluated (paper III). The single-cuff method 
detected greater reductions in brachial to aortic systolic BP levels and AIx by ramipril than by 
doxazosin. This interesting finding suggests that this method might be more sensitive for 
detecting treatment-induced changes on vascular stiffness compared with PWA by 
applanation tonometry. In addition, the oscillometric single-cuff method might be more 
sensitive to detecting changes in pulsatile flow that represent early structural changes. This is 
suggested by the greater reduction in aortic BP and AIx by ramipril, as compared to 
doxazosin as assessed by PWA with applanation tonometry.  
In conclusion, the oscillometric single-cuff appears suited for risk evaluation and for 
evaluation of the temporal changes of aortic BP and indices of arterial stiffness that are 
induced by antihypertensive treatment in the clinical setting. This method is easy to use 
compared to the more complicated and operator-dependent PWA method using applanation 
tonometry.  
 
5.4 ENDOTHELIAL FUNCTION IN RELATION TO RISK ASSESSMENT BY 
SCORE AND BY HYPERTENSION–INDUCED HEART DISEASE 
A cross sectional analysis evaluated indices of endothelial function and microvascular 
reactivity simultaneously in different vascular beds in relation to global CV risk, as assessed 
by SCORE, and by signs of hypertension-induced heart disease (paper IV). Our findings 
show that endothelial function in different vascular beds are all related to global CV risk, and 
thus the impaired endothelial function in hypertension is to some degree generalized and 
provides prognostic information in the hypertensive patient. Furthermore, the inverse 
relationship between FMD and SCORE was strengthened by adding carotid-femoral PWV 
into the statistical model, suggesting that PWV might improve CV risk assessment with 
SCORE (81,82).   
However, these different methods were poorly interrelated, suggesting that they represent 
different aspects of future CV risk. There are several potential reasons as to why the methods 
were poorly related. The key factor is that these methods measure endothelial function in 
different vascular beds. FMD represents endothelial function in larger conduit arteries, the 
PWA method with beta 2-adrenoceptor agonist represents smaller resistance arteries, LDF 
and iontophoresis the skin microcirculation, and the SEVR represents the coronary 
microcirculation. Vascular structure and function are different throughout the cardiovascular 
system. Local NO availability varies in different vascular beds, and larger conduit arteries 
have higher NO-synthase activity, as compared to smaller vessels (101). In resistance arteries, 
about one third of the EDV is mediated by NO, and about two thirds of the response is 
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mediated by endothelium hyperpolarizing factor and influence on potassium channels (13). In 
hypertensive subjects, there are signs of vascular remodeling with no relation to endothelial 
dysfunction (102,103). Thus, this might suggest that patients with mild-to-moderate 
hypertension might undergo remodeling in smaller arteries before the development of 
endothelial dysfunction. Also the stimulus for EDV is of importance. For FMD, the post-
ischemic reactive hyperaemia after cuff release causes local mechanical shear stress, which 
mediates NO release. In contrast, receptor-mediated stimulation is used for PWA with 
applanation tonometry and for iontophoresis and skin microcirculation. Also the route of 
administration, the dose, and the pharmacological agent can influence the vascular response.  
There was no relation between endothelial functional measurements and hypertension-
induced heart disease. This finding suggests that the risk factors related to endothelial 
dysfunction and SCORE and the risk factors related to hypertension-induced heart disease are 
not the same. For endothelial dysfunction, risk factors like smoking, hyperglycemia, and 
dyslipidemia are important, whereas for the development of LV hypertrophy and diastolic 
dysfunction, the influence of an activated RAAS and the sympathetic nervous system and BP 
are more important mediators.  
In conclusion, it is important to evaluate endothelial function in hypertensive patients because 
this might improve risk prediction. Endothelial functional measurements in different vascular 
beds are associated with global CV risk, as assessed by SCORE, but not to hypertension-
induced heart disease. However, these different methods are poorly interrelated. Thus, in a 
clinical setting the evaluation of arterial stiffness and endothelial function in conduit arteries 
should be evaluated simultaneously in hypertensive patients with mild or moderate risk, in 
addition to SCORE values, in order to further improve risk prediction.  
 
5.5 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
Hypertension is a major contributor to CV morbidity and mortality. Thus, BP reduction and 
improvement of preventive strategies in the clinical settings are of great importance to reduce 
risk of future CV events. Global risk assessment plays a central role in guiding the doctor in 
the evaluation of the hypertensive patient to improve decision-making regarding therapy, 
which is of outmost prognostic importance. In addition, it has an informative and educational 
value for the individual patient to learn more about the importance of life style changes in 
combination with the effects of treatment, to achieve an optimal BP.  
In paper I, our results showed an independent relation between arterial stiffness and 
hypertension induced heart disease. In addition, hypertension seems to be associated with 
vascular inflammation, which contributes to the evolution of arterial stiffness, in addition to 
BP. Thus, evaluation of vascular stiffness is important. We showed in paper III that the 
oscillometric single-cuff method is well suited to evaluate indices of arterial stiffness and 
could detect treatment-induced changes. Arterial stiffness is easy to evaluate by PWV, which 
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is an independent predictor of future CV events, and improves risk prediction (41,42).  
Furthermore PWV can be used to reclassify hypertensive patients with intermediate risk, as 
recommended in current guidelines (104). In addition, evaluation of central BP and wave 
reflection is important, as the aortic BP levels are different from brachial BP levels. Thus, the 
effects of treatment on central hemodynamics give additional information to conventional 
brachial BP measurements in order to improve risk evaluation and the effects of treatment in 
hypertensive patients. 
Our results from paper IV suggested that endothelial function in the macrocirculation and 
microcirculation is related to increased CV risk, assessed by the SCORE algorithm. Thus, 
endothelial dysfunction in patients with uncomplicated mild-to-moderate hypertension 
appears to be associated with increased CV risk and assessment of endothelial function may 
improve risk prediction. Increased LV mass is also a known CV risk factor, but in contrast, 
our results showed no relations between endothelial functional measurements and 
hypertension induced heart disease. Our results suggest that endothelial dysfunction and 
increased LV mass represents different aspects of CV risk.  
An improvement of risk evaluation where the information of vascular structure and function 
is taken in account in risk prediction is important.  In hypertensive patients with mild-to-
moderate risk the evaluation of arterial stiffness and endothelial function in different vascular 
beds could give additional information of future CV risk. It would be interesting to evaluate 
treatment effects on indices of arterial stiffness, as compared to BP reduction, in a 
randomized prospective outcome study in hypertensive patients with intermediate risk. 
Furthermore, it would be interesting to evaluate the contribution of adding PWV and AIx to 
the SCORE algorithm to improve risk evaluation in hypertensive patients.  
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6 CONCLUSIONS 
 
1. Hypertension induced heart disease is independently related to both BP and indices of 
arterial stiffness.  
 
2. Circulating inflammatory markers are elevated in hypertensive patients, and further 
increased in hypertensive patients who in addition are present with hypertension 
induced heart disease, with LV hypertrophy.  
 
3. Risk prediction in hypertensive patients may be improved by evaluation of 
endothelial function in addition to global CV risk, assessed by SCORE. 
 
4. Indices of endothelial function in different vascular beds are not closely interrelated, 
and are not related to hypertension-induced heart disease, suggesting that endothelial 
dysfunction and LV hypertrophy represents different aspects of CV risk. 
 
5. An oscillometric single-cuff method (Arteriograph) can be used to evaluate arterial 
stiffness and central haemodynamics, and this technique is well suited to evaluate the 
effects of antihypertensive treatment on central BP and indices of arterial stiffness.  
 
6. Endothelial function in macro- and microcirculation is unchanged by antihypertensive 
treatment in patients with hypertension and no signs of atherosclerotic disease. 
 
7. Circulating endothelial biomarkers and inflammatory markers are not influenced by 
antihypertensive therapy in patients with mild-to-moderate hypertension. Treatment 
induced improvement of endothelial function and systemic inflammation with 
antihypertensive treatment may require the presence of more advanced atherosclerotic 
disease. 
 
8. Blocking the RAAS by AT1-receptor blockers or ACE inhibitors improves indices of 
arterial stiffness more than antihypertensive treatment based on drugs blocking the 
effects of the sympathetic nervous system (alpha 1-adrenoceptor blockers or beta 1-
adrenoceptor blockers). 
 
9. Thus, drugs blocking the RAAS may offer an advantage in the treatment of 
hypertension beyond the effects on blood pressure reduction, as compared to other 
drug classes.  
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7 SVENSK SAMMANFATTNING 
 
Bakgrund: Högt blodtryck (hypertoni), leder till förändringar i blodkärlen och hjärtat vilket 
orsakar en ökad kärlstyvhet och förtjockning av hjärtmuskeln (vänsterkammarhypertrofi). 
Detta är kända riskfaktorer för framtida kardiovaskulär sjukdom. 
Regleringen av blodtrycket styrs bland annat av det sympatiska nervsystemet och renin-
angiotensin-aldosteron systemet (RAAS). Ett aktiverat RAAS leder till att angiotensin II 
bildas, vilket orsakar inflammation och strukturella förändringar i hjärta och kärl. Det finns 
därför mycket som talar för att blodtrycksmediciner som blockerar RAAS har positiva 
effekter utöver att sänka blodtrycket.  
Det övergripande syftet med detta projekt var att öka kunskapen om strukturella och 
funktionella kärlförändringar vid hypertoni hos människa. Vidare studerades hur blodtrycks-
handling påverkade kärlstyvhet och endotelfunktion. Blodtrycksmediciner som hämmar 
RAAS jämfördes med mediciner som hämmar det sympatiska nervsystemet för att studera 
behandlingseffekter utöver blodtryckssänkningen.  
Material och metoder: Denna avhandling baseras på två kliniska studier. I SILVHIA 
(Swedish irbesartan left ventricular hypertrophy investigation versus atenolol; delarbete I) 
studerades 115 patienter med hypertoni och vänsterkammarhypertrofi, som randomiserades 
till behandling med en angiotensin II-antagonist (irbesartan) eller en beta-receptorblockerare 
(atenolol) under 48 veckor. Dessa jämfördes med en grupp som hade hypertoni utan vänster-
kammarhypertrofi, och en grupp friska kontroller med normalt blodtryck. Olika mått på 
kärlstyvhet och cirkulerande biomarkörer för endotelcellsaktivitet och inflammation 
studerades vid studiestart samt efter 12 och 48 veckors behandling.  
I DoRa (Doxazosin-ramipril studien; delabete II-IV) studerades 71 patienter med obehandlad 
mild till måttlig primär hypertoni. Patienterna randomiserades till blodtryckssänkande 
behandling med en ACE-hämmare (ramipril) eller en alfa-receptor blockerare (doxazosin) 
under 12 veckor. Effekten på kärlstyvhet mättes med pulsvågsanalys och applanations-
tonometri (SphygmoCor), och med en oscillometrisk metod med blodtrycksmanschett 
(Arteriograph). Endotelfunktionen mättes samtidigt i flera kärlbäddar med olika icke invasiva 
metoder: flödesmedierad vasodilatation (större konduktanskärl), pulsvågsanalys med beta 2-
agonist stimulering (mindre resistenskärl), laser Doppler fluxmetri med jontofores (hudens 
mikrocirkulation), och pulsvågsanalys (kranskärlens mikrocirkulation). Undersökningarna 
genomfördes vid studiestart och efter 12 veckors behandling.  
Resultat och slutsatser: Patienter med hypertoni visade tecken på en ökad inflammatorisk 
aktivitet, mätt med cirkulerande biomarkörer, och en ökad kärlstyvhet. Inflammation var 
oberoende relaterad till blodtryck, och kärlstyvhet var oberoende relaterad till blodtryck och 
till vänsterkammarmassa (delarbete I). Behandling sänkte blodtrycket och minskade kärlstyv-
heten. Blodtrycksmediciner som hämmade RAAS minskade kärlstyvheten mer jämfört med 
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mediciner som hämmade det sympatiska nervsystemet (delarbete I och II). Däremot sågs inga 
effekter av behandling på endotelfunktionen mätt med de olika metoderna (delarbete II). 
Även cirkulerande biomarkörer för endotelcellsaktivitet och inflammation var oförändrade 
och behandlingen hade liten effekt (delarbete I och II). Den användarvänliga oscillometriska 
metoden med en blodtrycksmanschett (Arteriograph) var lämpad för att utvärdera effekter av 
behandling på kärlfunktion (delarbete III). Endotelfunktion mätt i olika kärlbäddar relaterade 
till riskdiagrammet SCORE, men det fanns ingen relation mellan endotelfunktion och 
hypertensiv hjärtsjukdom. Detta talar för att olika riskfaktorer bidrar till utvecklingen av 
endoteldysfunktion respektive hypertensiv hjärtsjukdom. Endotelfunktionsmätningar i olika 
kärlbäddar var inte relaterade, vilket talar för att endotelfunktionen i stora och små blodkärl 
inte är direkt jämförbara (delarbete IV).  
Sammanfattningsvis visar våra resultat att blodtrycksbehandling som hämmar RAAS har 
fördelaktiga tilläggseffekter utöver den blodtryckssänkande effekten hos patienter med primär 
mild till måttlig hypertoni. Detta talar för att patienter med hypertoni i första hand ska 
behandlas med blodtrycksmediciner som hämmar RAAS.   
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